ILIM
GEVA

Irish Life Investment Managers’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Irish Life Investment Managers’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$84K Buy
+2,000
New +$91.1K ﹤0.01% 1028

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Irish Life Investment Managers's GEVA Position: Q2 2013 in Review

Irish Life Investment Managers opened a new position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2013: 2,000 shares worth $84K. The stake represents ﹤0.01% of the portfolio and ranks #1028 among its holdings.

89 funds tracked by Wall St. Rank hold GEVA as of Q2 2013.

  • Irish Life Investment Managers held 2,000 shares of SYNAGEVA BIOPHARMA CORP COM STK (DE) worth $84K as of Q2 2013.
  • SYNAGEVA BIOPHARMA CORP COM STK (DE) was a new Irish Life Investment Managers position in Q2 2013.
  • SYNAGEVA BIOPHARMA CORP COM STK (DE) made up ﹤0.01% of Irish Life Investment Managers's portfolio in Q2 2013, its #1028 holding.
  • 89 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2013.

Based on Irish Life Investment Managers's 13F filing for Q2 2013, filed 13 Aug 2013.